Explain this page
Arphra AIPlain-English read on Boston Scientific Corporation’s valuation06-12today
- Boston Scientific (BSX) Registers a Bigger Fall Than the Market: Important Facts to Note3d
- Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months7d
- Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One8d
- Boston Scientific (BSX) Rises Higher Than Market: Key Facts16d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$442.74
+877.57% vs spot
Recommendation
Strong Buy
15 of 16 methods
Method spread
7bull8bear
±5% threshold
Analyst PT consensus: $91.33 (+101.66%)
Candlestick · 1Y
Open in chart workstation →BSX
45.29-55.29%H 109.50L 44.44MA50 54.92MA200 81.20Avg vol 12.8M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.76% | -3.97% | -20.08% | -34.82% | -52.63% | -52.50% | -55.29% | -16.19% | +3.88% | +98.21% | +957.87% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$28.46M
10 txns
Net flow
−$28.46M
Aftermarket
LiveLast trade
$45.45
Bid
$44.00
1 sh
Ask
$45.96
100 sh
Spread
$1.960
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $5.2B | $1.34B | $0.90 |
| Q4 Dec 2025 | $5.29B | $668M | $0.45 |
| Q3 Sep 2025 | $5.07B | $755M | $0.50 |
| Q2 Jun 2025 | $5.06B | $793M | $0.53 |
| Q1 Mar 2025 | $4.66B | $674M | $0.45 |
| Q4 Dec 2024 | $4.56B | $566M | $0.38 |
Analyst view
DB · price_targets + analyst_gradesConsensus target
$91.33
+101.66% upside
Low
$60.00
Median
$90.00
High
$120.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- Boston Scientific (BSX) Registers a Bigger Fall Than the Market: Important Facts to Notezacks.com·Jun 17, 2026
- Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Monthsfool.com·Jun 13, 2026
- Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset Oneseekingalpha.com·Jun 12, 2026
- Boston Scientific (BSX) Rises Higher Than Market: Key Factszacks.com·Jun 04, 2026
- Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Betzacks.com·Jun 04, 2026
- BSX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026businesswire.com·May 04, 2026
- BSX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026businesswire.com·May 04, 2026
- BSX DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - BSXnewsfilecorp.com·May 04, 2026
Recent analyst activity
DB- Jun 12, 2026GradeOverweight → OverweightBoston Scientific price target lowered to $65 from $90 at Piper SandlerPiper Sandler
- Jun 12, 2026PT$65.00Boston Scientific price target lowered to $65 from $90 at Piper SandlerPiper Sandler
- Jun 04, 2026PT$64.00Boston Scientific price target lowered to $64 from $85 at TruistTruist Financial
- Jun 02, 2026GradeBuy → BuyBoston Scientific price target lowered to $65 from $80 at BTIGBTIG
- Jun 02, 2026PT$65.00Boston Scientific price target lowered to $65 from $80 at BTIGBTIG
- Jun 01, 2026PT$70.00Boston Scientific price target lowered to $70 from $71 at CanaccordCanaccord Genuity
Financial scores
DBJun 20, 2026Altman Z
3.33
Safe
≥ 3.0 safe · 1.81–3.0 grey · < 1.81 distress
Piotroski F
7/9
Strong
≥ 7 strong · 4–6 average · < 4 weak
Peers
Total assets
$43.67B
Total debt
$12.42B
Cash & equiv
$2.05B
Operating CF
$4.53B
Free cash flow
$3.66B
Buybacks
$0
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Mahoney Michael F director, officer: Chairman, President & CEO | Sell | 1,200 | $112.87K | Feb 02, 2026 |
Mahoney Michael F director, officer: Chairman, President & CEO | Sell | 159,701 | $14.93M | Feb 02, 2026 |
Butcher Arthur C officer: EVP& Grp Pres, MedSurg & APAC | Sell | 17,313 | $1.76M | Dec 01, 2025 |
Zane Ellen M director | Sell | 12,891 | $1.27M | Nov 06, 2025 |
Fitzgerald Joseph Michael officer: EVP & Group Pres, Cardiology | Sell | 3,600 | $362.69K | Nov 03, 2025 |
Fitzgerald Joseph Michael officer: EVP & Group Pres, Cardiology | Sell | 16,928 | $1.69M | Nov 03, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $20.07B | $3.97B | $2.89B | $1.94 | +14.38% |
| FY 2024 | $16.75B | $2.64B | $1.85B | $1.25 | +11.07% |
| FY 2023 | $14.24B | $2.18B | $1.59B | $1.07 | +11.19% |
| FY 2022 | $12.68B | $1.82B | $698M | $0.45 | +5.50% |
| FY 2021 | $11.89B | $1.92B | $1.04B | $0.69 | +8.75% |